Donald R. Lannin

Yale University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

38h-index6.8kcitations194works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(96), Breast Lesions and Carcinomas(49), Global Cancer Incidence and Screening(33), Breast Implant and Reconstruction(26), Cancer Immunotherapy and Biomarkers(23)

Publications194 total

Abstract P3-07-09: Cost Differences of Hospital Admission vs. Home Recovery following Mastectomy
Clinical Cancer Research·2025· 1 cited
Age and Ethnic Disparities in Postmastectomy Immediate Breast Reconstruction: A cohort study from a Korean single center and National Cancer Database
2025Open Access
Abstract PO1-17-11: Trends in post-mastectomy reconstruction by age in Korea and among Asian-Americans
Cancer Research·2024
Supplemental Table 1 from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
Data from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
Supplemental Table 1 from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
Supplementary Figure Legends from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
supplemental Figures 1-5 from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
supplemental Figures 1-5 from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
Data from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
Supplementary Figure Legends from PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
Data from Cytoplasmic Estrogen Receptor in Breast Cancer
2023Open Access
CCR Translation for This Article from Cytoplasmic Estrogen Receptor in Breast Cancer
2023Open Access
Data from Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
Data from Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table 1 from Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table 1 from Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table 2 from Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
2023Open Access
Data from Cytoplasmic Estrogen Receptor in Breast Cancer
2023Open Access
Data from Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Anees B. Chagpar(16), Brigid K. Killelea(14), Nina Horowitz(12), Lajos Pusztai(11), Michael P. DiGiovanna(8), David L. Rimm(7), Tara Sanft(5), Erin Hofstatter(5), Sarah S. Mougalian(5), Bruce G. Haffty(5), Maysa Abu‐Khalaf(4), Jason R. Brown(4), Veerle Bossuyt(4), Lorraine Tafra(4), Melvin Swanson(4), Hallie Wimberly(3), Arlene N. Chua(3), Brandon Hayse(3), Holly F. Mathews(3), Meena S. Moran(3)